Microsoft word - rf cv updated 5.8.09.doc

CURRICULUM VITAE
Ronald E.P. Frenkel, M.D., F.A.C.S., F.I.C.S.
PERSONAL DATA


ACADEMIC RANK

2006-present Voluntary Associate Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine Voluntary Assistant Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine EDUCATION

Wayne State University School of Medicine, Detroit
POSTDOCTORAL TRAINING

Clinical Fellow in Glaucoma Massachusetts Eye and Ear Infirmary (Harvard Medical School), Boston Resident in Ophthalmology Kresge Eye Institute Medical and Surgical Retina with Mark S. Blumenkranz, MD Kresge Eye Institute (Wayne State University School of Medicine), Detroit Diabetic Retinopathy and Medical Retina with Robert Frank, MD Kresge Eye Institute (Wayne State University School of Medicine), Detroit Resident in Anesthesiology St. Elizabeth’s Hospital (Tuft’s University School of Medicine), Boston Resident in Internal Medicine Brigham and Women’s Hospital (Harvard Medical School), Boston
FLORIDA LICENSURE AND CERTIFICATION

Fellow, International College of Surgeons Fellow, American Academy of Ophthalmology Diplomate of the American Board of Ophthalmology Diplomate of the National Board of Medical Examiners
PROFESSIONAL POSITIONS

Peer Reviewer, Archives of Ophthalmology Principal Investigator, Ista Pharmaceuticals, CL-S&E-1205081-P, Multi Center, Efficacy and Safety of Bromfenac 0.09% Ophthalmic Solution QD vs Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery. Month, Investigator-Masked, Randomized, Multicenter, Parallel, Clinical Trial Comparing The Efficacy Of Combigan (fixed combination of 0.2% brimonidine tartrate and 0.5% timolol maleate ophthalmic solution) Versus Xalatan (Latanoprost 0.005% Ophthalmic Solution) In Subjects With Ocular Hypertension Or Open-Angle Glaucoma. Anecortave Acetate in Patients with Open Angle Glaucoma or Ocular Hypertension. Principal Investigator, Santen, A Randomized, Double-masked, Placebo- and Active- controlled, Parallel-group, Multi-center Dose-response Trial of DE-104 Ophthalmic Solution in Patients with Primary Open-angle Glaucoma or Ocular Hypertension. Allergan Protocol 206207-016: A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Principal Investigator, Genentech, FVF4165g, A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion. Principle Investigator, Sirion Therapeutics, A Phase 3 Multicenter, Randomized, Controlled, Double-Masked, Study of Safety and Efficacy of Vismed in Dry Eye Syndrome. 2007 Principal Investigator, Genentech, FVF4166g, A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion. 2007 Principal Investigator, Genentech, FVF4168g, A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Principal Investigator, Sirion Therapeutics, SRFR-001 A Phase II Multicenter, Randomized, Double-Masked, Placebo Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration. Principal Investigator, Regeneron Pharmaceuticals, Study VGFT-OD-0702, An Open Label, Long-Term, Safety and Tolerability of Intravitreal VEGF Trap in Subjects with Neovascular Age Related Macular Degeneration. Principal Investigator, Regeneron Pharmaceuticals, Study VGFT-OD-0605 Version VGFT-OD-0605.1 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Principal Investigator, Sirion Therapeutics, ST-603-006, An Open Label, Safety Evaluation of Cyclosporine A Ophthalmic Solution, 0.1% (ST-603) Administered Twice Daily For 12 Months to Subjects With Dry Eye Syndrome. Principle Investigator, Allergan Pharmaceuticals, 034, An Eighteen Week, Multicenter, Investigator-Masked, Randomized, Parellel-Group Study to Evaluate the Safety and Efficacy of Bimatoprost 0.03% (LUMIGAN®) Ophthalmic Solution Once-Daily (QD) Compared with Latanoprost 0.005% (Xalatan®) Ophthalmic Solution QD Following Six Weeks of Treatment with Xalatan® Principal Investigator, Sirion Therapeutics, ST-603-005, A Phase 3 Study of the Efficacy and Safety of Cyclosporine Ophthalmic Solution, 0.1% (ST-603) Compared to Vehicle in Subjects With Moderate to Severe Dry Eye Syndrome. Principal Investigator, Sirion Therapeutics, ST-601A-002a, A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery. Investigator, Sirion Therapeutics, ST-601A-001, A Phase 2b Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis. Principal Investigator, Regeneron Pharmaceuticals, Study VGFT-OD-0508, A Phase II Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated
Intravitreal Injections of VEGF Trap in Patients with Neovascular
Age Related Macular Degeneration.
Principal Investigator, A Phase II Multicenter, Double-Masked, Placebo-Controlled Parallel-Group, Dose Ranging Study of MOLI 1901 Ophthalmic Solution in Subjects with Moderate-to- Principal Investigator, Comparative of the Effective Dose Titration on the Incidence of Hyperemia Associated with Initiation of Bimatoprost Therapy, Unrestricted Scientific Grant. Principal Investigator, PRA International, Study MSI-1256F, A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate for Injection for the Treatment of Subfovea Choroidal Neovascularization Associated with Age-Related Macular Degeneration, Protocol #MSI-1256F-301/302. Principal Investigator, Allergan Pharmaceuticals, Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy with Travoprost 0.004% and Timolol 0.5% in Patients with Glaucoma and Ocular Hypertension. Principal Investigator, Allergan Pharmaceuticals, A Multicenter Evaluation of Methods to Reduce Hyperemia Associated with Bimatoprost Therapy for Glaucoma or Ocular Hypertension. Principal Investigator, Allergan Pharmaceuticals, Efficacy of Bimatoprost 0.03% in Patients Who are Low Responders to Latanoprost. Principal Investigator, Allergan Pharmaceuticals, Diurnal Curve with Bimatoprost 0.03% vs. Travoprost 0.004%. Principal Investigator, Allergan Pharmaceuticals, Brimonidine Purite 0.1% vs. Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost. Principal Investigator, Travoprost 0.004% With and Without Benzalkonium Chloride: A Comparison of Safety and Efficacy, Alcon Research., Ltd. 2003 – 2004 Principal Investigator, Allergan Pharmaceuticals, a Multi-Center, Double-Masked, Randomized, Parallel, 4-week Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution BID Compared with Concurrent Alphagan TID and Timolol BID (0.2% Brimonidine Tartrate and 0.5% Timolol) Ophthalmic Solutions and Alphagan (0.2% Brimonidine Tartrate) Ophthalmic Solution TID in Treatment Naïve Patients with Glaucoma or Ocular Hypertension. President, ISOCO, The International Society of Ocular Circulation and Oximetry. Clinical Project Director, National Eye Institute, Grant for Continuous Ocular Pressure Sensing System. Peer Reviewer, Ophthalmic Surgery, Lasers and Imaging. Principal Investigator, Pharmacia Corporation, a 12-week, multi-center, randomized, double-masked, three treatment parallel group comparison of the fixed combination of latanoprost and timolol vs. latanoprost vs. timolol in glaucoma patients with optic nerve head abnormalities and visual field defects. Member, American Society for Laser Medicine and Surgery. Principal Investigator, Pharmaceutical Research Network, LLC, AXIS P 00-035. Principal Investigator, Allergan Pharmaceuticals, a 48-month, multi-center, randomized, double-masked, placebo-controlled, clinical study to evaluate the effectiveness and safety of oral Memantine in doses of 20 mg. and 10 mg. in patients with chronic open-angle glaucoma at risk for glaucomatous progress, protocol #192944-005-01. Principal Investigator, Alcon Pharmaceuticals, S.T.A.R.T., Clinical protocol #CM-01-06. Principal Investigator, Alcon Pharmaceuticals, a 7-day, subject-masked, ocular comfort and hyperemia evaluation of Travatan 0.004% compared to Lumigan 0.03% in subjects with open-angle glaucoma or ocular hypertension (C-01-52). 2000 -present Volunteers In Medicine Provider 2000-2002 Principal Investigator, Merck Pharmaceuticals Study, a pilot study evaluating the Effect of Dorzolamide and Brimonidine on the Blood Flow in the Juxtapapillary and Neuroretinal Rim Areas in Glaucomatous Eyes. 1999 –present Eye Care America Volunteer Provider 1999 Moderator, Glaucoma Laser Surgery session at The Association for Research and Vision in Ophthalmology, Annual Meeting, Fort Lauderdale, Florida, May 10, 1999. Principal Investigator, Pharmacia and Upjohn, Study 9700PG071, a randomized five-year post-marketing safety study of Xalatan compared to "usual care" in patients with open-angle glaucoma and ocular hypertension Scientific Reviewer, American Journal of Ophthalmology Member Glaucoma 2001 Committee, Florida Society of Ophthalmology Clinical Investigator, Family Study of Macular Degeneration, in association with Epidemiology Unit, Massachusetts Eye and Ear Infirmary Principal Investigator, Alcon Pharmaceuticals, Study C-96-69, a Three-Month, Multicenter, Triple-Masked, Parallel Study for Safety and Efficacy of once-daily-dosed Timolol Gel Forming Solution 0.5% compared to bid-dosed Timoptic XE 0.5% Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Scientific Reviewer, Ophthalmic Surgery and Lasers Scientific Reviewer, Investigative Ophthalmology and Visual Science 1994 - present Member, Medical Executive Committee, Martin Memorial 1994- present Director, Eye Research Foundation, Stuart, Florida 1994 -present Member, Third Party Liaison Committee (for Glaucoma issues), Florida Society of Ophthalmology, (which interacts with the State of Florida Medicare Carrier) Vice-President Ophthalmic Inventors Society Member, Membership Committee, Florida Society of Ophthalmology Member, Continuing Medical Education Committee, Martin Memorial Hospital Member, Utilization Management Committee, Martin Memorial Hospital Principal Investigator, Merck, Sharp, and Dohme, Study TIM #266, Comparison of the efficacy and tolerability of Timolol and Levobunolol in patients with increased intraocular pressure and at sufficient risk to require therapy Member, Board of Directors, Florida Society of Ophthalmology President, Treasure Coast Ophthalmology Society Quality Assurance Committee, Coastal Surgical Care Risk Management Committee, Martin Memorial Hospital Principal Investigator, Allergan Pharmaceuticals, Study LBUN-210-6711, Comparing 0.25% Levobunolol q.d. with 0.25% Timolol q. Investigator, Allergan Medical Optics Intraocular Lenses Book Reviewer, Archives of Ophthalmology Principal Investigator, Allergan Pharmaceuticals, Study LBUN-181-6618, The Safety and Efficacy of Once-Daily Levobunolol Therapy in Subjects Previously Treated with Timolol Twice-Daily. Clinical Fellow in Ophthalmology, Harvard Medical School, Boston Principal Investigator, Allergan Pharmaceuticals, Study FMLF-108-6591, 0.25% Fluoromethalone for the Control of Inflammation Following Argon Laser Trabeculoplasty Clinical Fellow in Medicine, Harvard Medical School, Boston
NATIONAL AWARDS

Lifelong Education for the Ophthalmologist (LEO) Continuing Education Recognition Award, American Academy of Ophthalmology Achievement Award, American Academy of Ophthalmology

VISITING APPOINTMENTS

Glaucoma and anterior segment consultant Aravind Eye Hospital, Madurai, India
PROFESSIONAL SOCIETY MEMBERSHIPS

2009-present Advisory Board, Martin Memorial Foundation 2008-2009 2001-present American Society for Laser Medicine and Surgery 1991-2009 Member-Board of Directors, Martin Memorial Foundation 1990 California Association of Ophthalmology 1987- Association for Research in Vision and Ophthalmology
HOSPITAL STAFF APPOINTMENTS

HCA Medical Center of Port St. Lucie – Courtesy Staff Martin Memorial Hospital – Invitational Staff: Special Services Martin Memorial Surgery Center – Associate Staff 2005-present Member, Magnificent Enterprise, Vassar College 1998 Chair, Foundations, Martin Memorial Hospital Cancer Center, Steering Committee Listed in Who’s Who in the South and Southwest, 24th Ed. Honorary Chairperson, An Evening at the Pops, for Martin Memorial Medical Center, January 19, 1993 Member, Major Gifts Committee, Martin Memorial Foundation Member, Board of Trustees, Martin Memorial Foundation
TEACHING EXPERIENCE

Hospital
Supervised clinical training of Massachusetts Eye and Ear Infirmary Glaucoma Service residents Development of Glaucoma Clinic; Fellow and Resident Training, Aravindi Hospital, Madurai, India Course Director, American Academy of Ophthalmology, Frontiers in Ocular Blood Flow in Glaucoma: Principles and Practice. Instructor, American Academy of Ophthalmology, Combined Management of Chronic Open-Angle Glaucoma and Cataract
SYMPOSIA PANEL PARTICIPATION

1. Why Do Patients Go Blind from Glaucoma and What Can We Do About It? Glaucoma Research Foundation, Amelia Island, Florida, February 20, 1999. 2. Moderator ARVO Special Interest Group (with Georg Michelson, University of Erlangen Nurnberg, Erlangen Germany): Ocular Blood Flow and Systemic Blood Pressure in Glaucoma, ARVO, Ft. Lauderdale, FL, April, 2004. 3. Moderator (with Leopold Schmetterer, University of Vienna, Vienna, Austria) ARVO Special Interest Group: Controversies in Blood Flow and Neuroprotection, ARVO, Ft. Lauderdale, FL, May, 2005. CURRENT PUBLICATIONS

1. Frenkel, R.E.P., Brodsky, M.C., and Spoor, T.C.: Adult onset cyclic esotropia and optic atrophy. J. Clinical Neuro-Ophthalmology 6: 27-30, 1986. 2. Frenkel, R.E.P. and Spoor, T.C.: Visual loss and intoxication. Survey of 3. Frenkel, R.E.P. and Shin, D.H.: Prevention and management of delayed suprachoroidal hemorrhage after filtration surgery. Archives of Ophthalmology. 104: 1459-1463, 1986. 4. Frenkel, R.E.P. and Shin, D.H.: Fluorouracil and suprachoroidal hemorrhage. Archives of Ophthalmology. 105: 169, 1987. 5. Frenkel, R.E.P., Hong, Y.J., and Shin, D.H.: Misuse of eye drops due to interchanged caps. Archives of Ophthalmology. 106: 17, 1988. 6. Frenkel, R.E.P. and Shin, D.H.: Suprachoroidal hemorrhage. Ophthalmic 7. Brodsky, M.C., Frenkel, R.E.P., and Spoor, T.C.: A familial intracranial aneurysm presenting as a subtle, stable third nerve palsy. Archives of Ophthalmology. 106: 173, 1988. 8. Frenkel, R.E.P. and Shin, D.H.: Suprachoroidal hemorrhage after glaucoma filtering surgery. American Journal of Ophthalmology. 104: 444, 1987. 9. Frenkel, R.E.P., Hong, Y.J, and Shin, D.H.: Evaluation of the accuracy of the Tono-pen. Investigative Ophthalmology and Visual Science (Suppl) 29: 237, 1988. 10. Frenkel, R.E.P., Hong, Y.J., and Shin, D.H.: Comparison of the Tono-pen to the Goldman applanation tonometer. Archives of Ophthalmology. 106: 750-753, 1988. 11. Melamed, S., Frenkel, R.P.E., Krug, J.H., and Allingham, R.: Trabeculectomy with resection of ciliary processes in glaucoma following scleral buckling. Ophthalmic Surgery. 19: 506-507, 1988. 12. Frenkel, R.E.P.: Evaluation of the relative afferent pupillary defect in pseudotumor cerebri in regard to surgical intervention. Archives of Ophthalmology. 107: 634-635, 1989. 13. Shin, D.H., and Frenkel R.E.P.: The use of viscuelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surgery. 20: 895, 1989. 14. Frenkel, R.E.P., Bohn, J.L., Shin, D.H., Epstein, D.L., Hertzmark, E., and Lee, S.: Influence of the number of laser burns on the result of argon laser trabeculoplasty. Investigative Ophthalmology and Visual Science (Suppl) 32: 741, 1991. 15. Frenkel, R.E.P.: Removable sutures in the titration of trabeculectomy bleb function. J. of Glaucoma. 1: 290-292, 1992. 16. Simone, P.A., Shin, D.H., Hughes, B.A., Johnston, E.W., Reed, S.Y., Sygiel, B.R., and Frenkel, R.E.P.: Topical beta blocker use and associated systemic side effects in a tertiary glaucoma practice. Investigative Ophthalmology and Visual Science. 36: 4, S 218, 1995. 17. Birt, C.M., Shin, D.H., Reed, S.Y., McCarty, B., and Frenkel, R.E.P.: One vs. two doses of 1.0% Apraclonidine for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. Can. J. Ophthal. 30: 266-269, 1995. 18. Frenkel, R.E.P. and Simmons, R.J.: Neovascular Glaucoma. Glaucoma. 5: 19. Shin, D.H., Frenkel, R.E.P., David, R., Cheetham, J.K., and the Fluormetholone – Laser Trabeculoplasty Study Group: Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty. American Journal of Ophthalmology. 122: 349-354, 1996. 20. Frenkel, R.E.P. and Latina, M.: Glaucoma drainage implant studies updated. 21. Levin, D.S., Shin, D.H., Lee, D., Kim, C., Chung, H.S., and Frenkel, R.E.P.: Outcomes of Argon Laser Trabeculoplasty in patients with and without Post-ALT Intraocular Pressure Spike. Investigative Ophthalmology and Visual Science. 38: 4, S 168, 1997. 22. Shin, D.H., Frenkel, R.E.P., David, R., et al.: Effect of Topical Anti- inflammatory Treatment on the Outcome of Laser Trabeculoplasty. Outcomes of Argon Laser Trabeculoplasty. Ophthalmology Digest. June, 1977. 23. Frenkel, R.E.P., Shin, D.H., Epstein, D.L., Hertzmark, E., Bohn, J.L., and Hong, Y.J.: Laser trabeculoplasty: How Little is Enough? Ophthalmic Surgery and Lasers. 28: 900-904, 1997. 24. Patel, H.C., Ren, J., Shin, D.H., Chung, H.S., Hong, Y.J., Rho, S.H., and Frenkel, R.E.P.: Comparative Efficacies of Apraclonidine, Brimonidine, Pilocarpine, and Latanoprost in Prophylaxis of IOP spikes Following ALT or YAG Capsulotomy. Investigative Ophthalmology and Visual Science. 39: 4, S 2196, 1998. 25. Frenkel, R.E.P., Shin, D.H., and Kim, C.: Does the Visual Acuity Correlate with the Central 1.4 Degrees of Visual Field and the Foveal Sensitivity in Advanced Glaucoma Patients? Investigative Ophthalmology and Visual Science. 39: 4, S 494, 1998. 26. Kim, Y., Glover, B.K., Shin, D.H., Lee, D., Frenkel, R.E.P., and Abreu, M.M.: Effect of Topical Anti-inflammatory Treatment on the Long-term Outcome of Laser Trabeculoplasty. American Journal of Ophthalmology, Vol. 126, No. 5, November 1998. 27. Frenkel, R.E.P., and Chen, J.: Rates of Glaucoma Medication Intolerance and Ineffectiveness. J. Glaucoma. 8:1, Suppl. 1999, pg. S 14. 28. Frenkel, R.E.P., and Chen, J.: Frequency of Glaucoma Medication Intolerance and Ineffectiveness. Investigative Ophthalmology and Visual Science. 40: 4, S 514, 1999. 29. Shin, D., Garadi, R., Silver, L.H., Ratliff, M., von Tress, M., The Timolol Gel Forming Solution Study Groups (including Frenkel, R.E.P.).: Timolol Gel Forming Solution (0.25% and 0.5%): A New Once-Daily Formulation of Timolol Maleate for the Reduction of Elevated Intraocular Pressure. Investigative Ophthalmology and Visual Science. 40: 4, S 513, 1999. 30. Gosiengfiao DH, Latina MA, Tumbocon JA, Frenkel RE. A Crossover Study to Evaluate the Effect of Topical Dorzolamide and Brimonidine on Ocular Blood Flow in Patients with Primary Open Angle Glaucoma Using the Heidelberg Retinal Flowmeter. E-3316. Investigative Ophthalmology and Visual Science, 43:12, 3784, 2002. 31. Latina, MA, Gosiengfiao DH, Frenkel RE, Tumbocon JA. The Effect of Topical Dorzolamide on Ocular Blood Flow in Patients with Normal Tension Glaucoma using the Heidelberg Retinal Flowmeter. E-322. Investigative Ophthalmology and Visual Science, 43:12, 3793, 2002. 32. Mucciolo JT, Frenkel REP, Latina MA, Gosiengfiao D, Tumbocon JA. Comparison of Two Image Acquisition Protocols for Scanning Laser Doppler Flowmetry in a Glaucoma Population. E-335. Investigative Ophthalmology and Visual Science, 43:12, 3798, 2002. 33. Frenkel, REP, Mucciolo JT: Comparison of Two Image Acquisition Protocols for Scanning Laser Doppler Flowmetry in Glaucoma Patients. Investigative Ophthalmology and Visual Science, 2003; 44:ARVO E-Abstract 2152. 34. Mucciolo, JT, Frenkel, REP: The Effect of Selective Laser Trabeculoplasty (SLT) in Open Angle Glaucoma Patients With Previous 360 Degree Argon Laser Trabeculoplasty (ALT) Treatment. Investigative Ophthalmology and Visual Science, 2003; 44: ARVO E-Abstract 2003. 35. Frenkel, REP, Latina, NA, Mucciolo, J.: Standardized Image Acquisition Protocol for Scanning Laser Doppler Flowmetry (SLDF). Ocular Circulation, 2003. 36. Mucciolo, JT and Frenkel, REP. Cost Savings in the Lipid Class of Anti- Glaucoma Medications: Looking at Them From a New Angle. Investigative Ophthalmology and Visual Science, 2004. 44:ARVO E-Abstract 5558. 37. Frenkel, REP, Toler, AR, Mucciolo, JT. Blood Pressure Parameters in Patients with Normal Tension Glaucoma and Systemic Hypertension. Investigative Ophthalmology and Visual Science, 2004 45: E-Abstract 4435. 38. Reistad, Shields, Campbell, Ritch, Wang, Wand, and the American Glaucoma Society Pigmentary Glaucoma Iridotomy Study Group (including Ronald E.P. Frenkel, M.D.): The Influence of Peripheral Iridotomy on the Intraocular Pressure Course in Patients with Pigmentary Glaucoma. Journal of Glaucoma, 14:255-259, 2005. 39. Frenkel, REP and Toler, AR: Fluctuations in Blood Pressure Are Associated With Glaucoma Progression in Patients With Systemic Hypertension and Normal Tension Glaucoma. Investigative Ophthalmology and Visual Science, 2005 46: E-Abstract 1307. 40. Toler, AR and Frenkel REP: Clinical Usefulness of Pachymetry in Known Glaucoma Patients. Investigative Ophthalmology and Visual Science, 2005 41. Giuliano, Frenkel, REP and Toler, AR: Combination Therapy for Treatment of Radiation Retinopathy, Investigative Ophthalmology and Visual Science, 2006 E-Abstract 5206. 42. Houle, L and Frenkel, REP and Toler, AR: Incidents of Transient NLP Following Macugen Treatment in Patients with Glaucoma and Glaucoma Suspects, Investigative Ophthalmology and Visual Science, 2006. E-Abstract 4276. 43. Toler, AR and Frenkel, REP: IOP Effects of Macugen in Glaucoma Patients, Investigative Ophthalmology and Visual Science, 2006. E-Abstract 432. 44. Schoenholtz, S and Frenkel, REP, and Toler, AR: Is Low Nocturnal Diastolic Perfusion Pressure a Risk Factor for Glaucoma? Investigative Ophthalmology and Visual Science, 2006. E-Abstract 4783. 45. Schoenholtz, S., Frenkel, REP, Toler, AR: Should We Be Concerned with Post-Injection IOP Spikes from Lucentis, Investigative Ophthalmology and Visual Science, 2007. E-Abstract 5635. 46. Toler, AR, Frenkel, REP, Mani, L: Is IOP a Concern Post-Injection of Macugen, Avastin, or Lucentis. Investigative Ophthalmology and Visual Science, 2007, E-Abstract 5998. 47. Giuliano, A, Frenkel, REP, Avery, R, Thomas G, Toler, AR: Contralateral Effect from Intravitreal Avastin for Treatment of Wet AMD. Investigative Ophthalmology and Visual Science, 2007, E-Abstract 6052. 48. Mundorf, TK, Noecker, R, Earl, M, Frenkel, REP: Brimonide Purite 0.15%, Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost. Investigative Ophthalmology and Visual Science, 2007, E-Abstract 5560. 49. Frenkel, REP, Toler, AR, Mani, L and Frenkel, M: IOP Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma. American Journal of Ophthalmology, Vol 143, June 2007. 50. Frenkel, REP, Toler, A.: IOP Spikes Following Anti-VEGF Injections. Frenkel R, Frenkel M, Toler A, Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension, Journal: BMC Ophthalmology Year: 2007 Vol: 7 Issue: 1 Pages/record No.: 16. 52. Frenkel, REP, Toler, AR and Frenkel, M: Pharmacoeconomic Analysis of Prostaglandin and Prostamide Therapy for Patients with Glaucoma and Ocular Hypertension. BioMed Central Ophthalmology 2007, 7:16. 53. Frenkel, REP, Noecker, R, Craven, R.: Evaluation of Circadian Control of Intraocular Pressure After a Single Drop of Bimatoprost 0.03% or Travoprost 0.004%. Current Medical Research and Opinion. 2008 Apr;24(4):919-23. Epub 2008 Feb 54. Frenkel, REP, Toler, AR, Mani, L and Frenkel, M., IOP Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma, American Journal of Ophthalmology, Vol 145, January 2008. 55. R.E. Frenkel, L. Mani, A. Reyes., Complications of a Surgeon’s Initial Intravitreal Injections, Investigative Ophthalmology and Visual Science, 2008, E-Abstract. 56. A. Giuliano, A. Reyes, L. Mani, R.E.P. Frenkel, A.R. Toler, M.P.C. Frenkel. Does Central Corneal Thickness Change When IOP Significantly Increases? Investigative Ophthalmology and Visual Science, 2009, E-Abstract. 57. Durezol Study Group, Superiority Of Vismed® (Sodium Hyaluronate Ophthalmic Solution 0.18%) Compared With Its Vehicle In The Treatment Of The Signs And Symptoms Of Dry Eye Disease, Investigative Ophthalmology and Visual Science, 2009, E-Abstract. 58. M.P. Frenkel, R.E.P. Frenkel, S. Haji, A. The Effect of Prophylactic Use of IOP Lowering Medication on IOP Spikes After Intravitreal Injections, Investigative Ophthalmology and Visual Science, 2009, E-Abstract. 59. R.E. Frenkel, A, M. Jaeger, R. Kline-Schroeder, M.A. Latina, J.M. Parel, M.P.C. Continuous Monitoring of Intraocular Pressure with an Implantable Device, Frenkel, Investigative Ophthalmology and Visual Science, 2009, E-Abstract. 60. R.E.Frenkel, CLEAR-IT 2: Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap Eye in Patients With Neovascular Age-Related Macular Degeneration: Predictive Factors for Visual Acuity Outcome at One Year, 2009 E-Abstract 61. R.E.Frenkel, VEGF Trap-Eye Vision-Specific Quality of Life Through 52 Weeks in Patients With Neovascular AMD in CLEAR-IT 2: A Phase 2 Clinical Trial, 2009 E-Abstract 62. R.E.Frenkel, A Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap-Eye in Patients With Neovascular Age-Related Macular Degeneration: Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) Outcomes at 1 Year, 2009 E-Abstract. Intraocular Lens Pressure Monitoring Device, April 9, 1991. CHAPTERS

Frenkel, R.E.P. and Spoor, T.C.: Diagnosis and management of traumatic optic neuropathies. In Bosniak, S.L. and Smith, B.C. (eds.) Advances in Ophthalmic Plastic and Reconstructive Surgery, Vol. 6, Orbital Trauma, Part I, Pergamon Press, New York, pp. 71-90, 1987. Frenkel, R.E.P. and Spoor, T.C.: Neuro-ophthalmologic manifestations of trauma. In Spoor, T.C. and Nesi, FAA. (eds.) Management of Ocular, Orbital, and Adnexal Trauma. Raven Press, New York, pp. 195-245, 1988. Frenkel, R.E.P., Haji, S., Toler, A., Frenkel M., The Glaucoma Book, in Press 2009.
PRESENTATIONS

1. Cardiovascular effects of inhalational anesthetics. St. Elizabeth’s Hospital, 2. Adult onset cyclic esotropia and optic atrophy. 30th Annual Clinic Days, Kresge Eye Institute, Detroit, Michigan, May 10, 1985. 3. Adult onset cyclic esotropia and optic atrophy. Seventh Annual Upper Midwest Neuro-Ophthalmology Group Meeting, with Spoor, T.C., Chicago, Illinois, July 26, 1985. 4. Adult onset cyclic esotropia and optic atrophy. Presented at the American association of Certified Orthoptists, with Spoor, T.C., San Francisco, California, October, 1985. 5. Misdiagnosis of meningiomas. Exhibit. American Academy of Ophthalmology, with Spoor, T.C., Nesi, FAA., and Hartel, W., San Francisco, California, September-October 1985. 6. The Foster Kennedy Syndrome Revisited. 31st Annual Clinic Days, Kresge Eye Institute, Detroit, Michigan, June 6, 1986. (3rd Prize) 7. Amaurosis Fugax. Harper Hospital, Detroit, Michigan, November 18, 1986. 8. Prevention and management of delayed suprachoroidal hemorrhage after filtration surgery. 32nd Annual Clinic Days, Kresge Eye Institute, Detroit, Michigan, May 29, 1987. 9. Continuous monitoring of intraocular pressure, Massachusetts Institute of 10. Lectures in Glaucoma, Aravind Eye Hospital, Madurai, India, January- 11. Evaluation of the accuracy of the Tono-Pen. Poster. Association for Research in Vision and Ophthalmology, Sarasota, Florida, May 4, 1988. 12. Ophthalmology in India, Grand Rounds, Massachusetts Eye and Ear Infirmary, 13. Glaucoma and Laser Surgery, Martin Memorial Hospital, January 31, 1990. 14. Ophthalmology Update for Non-Ophthalmologists, Grand Rounds, Martin 15. Low-Dose Laser Trabeculoplasty, Palm Beach Ophthalmologic Society, 16. The Red Eye. Martin Memorial Hospital, April, 1990. 17. Influence of the Number of Laser Burns on the Result of Argon Laser Trabeculoplasty. Poster. Association for Research in Vision and Ophthalmology, Sarasota, Florida, April 29, 1991. 18. Influence of the Number of Laser Burns on the Result of Argon Laser Trabeculoplasty. Annual Ophthalmology Clinical and Scientific Meeting of the Massachusetts Eye and Ear Infirmary Alumni Association, Boston, Massachusetts, May 17, 1991. 19. Setons in Glaucoma, Palm Beach Ophthalmologic Society, September 25, 20. Setons in Glaucoma Surgery, Treasure Coast Ophthalmology Society, 21. Laser Trabeculoplasty, How Many Spots Do I Need? Treasure Coast Ophthalmology Society, February 13, 1992. 22. What’s New in Glaucoma in 1992? Martin Memorial Hospital, April 1, 1992. 23. The Diabetes 2000 Project and the Florida Society of Ophthalmology, Martin 24. Ultraviolet Light and the Eye, Martin Memorial Hospital, January 6, 1993. 25. Ectropion Uveae and Glaucoma, Nantucket Glaucoma Conference, Nantucket, 26. Laser Trabeculoplasty – How Little is Enough? Nantucket Glaucoma Conference, Nantucket, Massachusetts, August 13, 1993. 27. Topical Beta Blocker Use and Associated Systemic Side Effects in a Tertiary Glaucoma Practice, Association for Research in Vision and Ophthalmology, Fort Lauderdale, May 15, 1995, (with Simone, et al). 28. Trusopt – A New Glaucoma Drug, Treasure Coast Ophthalmology Society, 29. Does the visual acuity correlate with the central 1.4 degrees of visual field and the foveal sensitivity in advanced glaucoma patients? (with D.H. Shin and C. Kim), American Glaucoma Society, August 1, 1996, Vancouver, Canada. 30. Loss of central vision in patients with advanced glaucoma, Treasure Coast Ophthalmologic Society, Stuart, Florida, October 9, 1996. 31. Outcomes of Argon Laser Trabeculoplasty in patients with and without Post- ALT Intraocular Pressure Spike: Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 11, 1997 (with Levin, et al). 32. Tube shunts in glaucoma. Palm Beach Ophthalmologic Society, July 29, 1997, 33. Rates of Glaucoma Medication Intolerance and Ineffectiveness. American Glaucoma Society, February 19-20, 1999, Amelia Island, Florida. 34. Frequency of Glaucoma Medication Intolerance and Ineffectiveness, Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 11, 1999. 35. Timolol Gel Forming Solution: A New Once-Daily Formulation of Timolol Maleate for the Reduction of Elevated Intraocular Pressure, Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 11, 1999, (with Shin, D. et al). 36. The Effect of Topical Dorzolamide and Brimonidine on Retinal Capillary Blood Flow: A Crossover Study in Patients With Open-Angle Glaucoma (with M.A. Latina, J.A. Tumbocon, D. Gosiengfiao), American Academy of Ophthalmology, New Orleans, Louisiana, November 13, 2001. 37. The Effect of Topical Dorzolamide and Brimonidine on Retinal Capillary Blood Flow: A Crossover Study in Patients with Open-Angle Glaucoma (with M.A. Latina, J.A. Tumbocon, D. Gosiengfiao), American Glaucoma Society, San Juan, Puerto Rico, Feb – March, 2002. 38. Efficacy of Bimatoprost 0.03% as Adjunctive Therapy in Glaucoma Patients using Latanoprost 0.005%, American Glaucoma Society, San Juan, Puerto Rico, Feb – March, 2002. 39. Comparative Cost of Prostaglandin and Prostamide Therapy in Treating Patients with Elevated Eye Pressure, American Glaucoma Society, San Juan, Puerto Rico, Feb – March, 2002. 40. The Effect of Topical Dorzolamide on Ocular Blood Flow in Patients with Normal Tension Glaucoma using the Heidelberg Retinal Flowmeter (with M.A. Latina, D.H. Gosiengfiao, J.A. Tumbocon), Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May, 2002. 41. Comparison of Two Image Acquisition Protocols for Scanning Laser Doppler Flowmetry in a Glaucoma Population (with J.T. Mucciolo, M.A. Latina, D. Gosiengfiao, J.A. Tumbocon), Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May, 2002. 42. A Crossover Study to Evaluate the Effect of Topical Dorzolamide and Brimonidine on Ocular Blood Flow in Patients with Primary Open Angle Glaucoma Using the Heidelberg Retinal Flowmeter (with D.H. Gosiengfiao, M.A. Latina, J.A. Tumbocon), Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May, 2002. 43. Cost Comparison of Prostaglandin and Prostamide Therapy in Treating Patients with Glaucoma or Ocular Hypertension, American Academy of Ophthalmology, Orlando, Florida, October 22, 2002. 44. Comparison of Two Image Acquisition Protocols for Scanning Laser Doppler Flowmetry in Glaucoma Patients (with J.T. Mucciolo), Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May, 2003 45. The Effect of Selective Laser Trabeculoplasty (SLT) in Open Angle Glaucoma Patients With Previous 360 Degree Argon Laser Trabeculoplasty (ALT). Treatment. (with J.T. Mucciolo) Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May, 2003 46. Blood Flow Response to Topical Dorzolamide Therapy in Normal-Tension Glaucoma Patients, American Academy of Ophthalmology, Anaheim, California, November, 2003. 47. Evaluation of a New Standardized Image Acquisition Protocol for Scanning Laser Doppler Flowmetry, American Glaucoma Society, Sarasota, FL, March, 2004. 48. Systemic Blood Pressure Parameters in Patients with Normal-Tension Glaucoma and Systolic Hypertension, American Glaucoma Society, Sarasota, FL, March 2004. 49. Looking at Cost Savings in the Lipid Class of Anti-Glaucoma Medications from a New Angle, American Glaucoma Society, Sarasota, FL, March, 2004. 50. Moderator Association for Research in Vision and Ophthalmology Special Interest Group (with Georg Michelson, University of Erlangen Nurnberg, Erlangen Germany): Ocular Blood Flow and Systemic Blood Pressure in Glaucoma, ARVO, Ft. Lauderdale, FL, April 2004. 51. Blood Pressure Parameters in Patients with Normal Tension Glaucoma and Systemic Hypertension, Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, April 2004. 52. Cost Savings in the Lipid Class of Anti-Glaucoma Medications, Looking at them from a New Angle. Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, April 2004 53. Systemic Blood Pressure Abnormalities in Glaucoma, ARVO Special Interest Group, Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, April 2004 54. Is Pachymetry Useful In Known Glaucoma Patients?, American Glaucoma 55. Blood Pressure Fluctuation in Patients With Normal Tension Glaucoma and Systemic Hypertension is Associated with Glaucoma Progression, American Glaucoma Society, Snowbird, UT, March, 2005 56. Fluctuations in Blood Pressure Are Associated With Normal Tension Glaucoma Progression in Patients With Systemic Hypertension. May 2005 57. Clinical Usefulness of Pachymetry in Known Glaucoma Patients, May 2005 58. Moderator (with Leopold Schmetterer, University of Vienna, Vienna, Austria) Association for Research in Vision and Ophthalmology Special Interest Group: Controversies in Blood Flow and Neuroprotection, Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, May, 2005. 59. Frenkel, REP and Toler, AR: Fluctuations in Blood Pressure Are Associated With Glaucoma Progression in Patients With Systemic Hypertension and Normal Tension Glaucoma, Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, May, 2005. 60. Clinical Implication of Pachymetry in Patients with a History of Chronic Open Angle Glaucoma, American Academy of Ophthalmology, Chicago, IL, October 2005. 61. Advanced Diagnostics in Eye Care, Treasure Coast Optometric Society, Stuart 62. Giuliano, Frenkel, REP and Toler, AR: Combination Therapy for Treatment of Radiation Retinopathy, Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2006. 63. Houle, L and Frenkel, REP and Toler, AR: Incidents of Transient NLP Following Macugen Treatment in Patients with Glaucoma and Glaucoma Suspects, Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, 2006. 64. Toler, AR and Frenkel, REP: IOP Effects of Macugen in Glaucoma Patients, Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, 2006. 65. Schoenholtz, S and Frenkel, REP, and Toler, AR: Is Low Nocturnal Diastolic Perfusion Pressure a Risk Factor for Glaucoma? Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL, 2006. 66. Continuous IOP Measurement System, Joint Meeting of the American Academy of Ophthalmology and Asia Pacific Academy of Ophthalmology, Las Vegas, Nevada, November 11, 2006. 67. Low Nocturnal Diastolic Perfusion Pressure is a Risk Factor for Glaucoma, Joint Meeting of the American Academy of Ophthalmology and Asia Pacific Academy of Ophthalmology, Las Vegas, Nevada, November 11, 2006. 68. Incidence of Transient NLP Following Macugen or Avastin Treatment Joint Meeting of the American Academy of Ophthalmology and Asia Pacific Academy of Ophthalmology, Las Vegas, Nevada, November 11, 2006. Sanguily, J and Frenkel, REP: Radiation Retinopathy and Hyperbaric Oxygen Therapy, Diversified Clinical Services, Feb 2007. 70. Should We Be Concerned with Post-Injection IOP Spikes from Lucentis, 71. Is IOP a Concern Post-Injection of Macugen, Avastin, or Lucentis, ARVO, 72. Contralateral Effect from Intravitreal Avastin for Treatment of Wet AMD, 73. Brimonidine Purite 0.15%, Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost, ARVO, Fort Lauderdale, FL, May 2007. 74. Macular Disease Update, Treasure Coast Optometric Society, Stuart, FL, April 75. CLEAR-IT-2: Interim Results of the Phase II, Randomized, Controlled Dose- and Interval-ranging Study of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age-Related Macular Degeneration, ARVO, Fort Lauderdale, FL, May 2007. 76. CLEAR-IT-2: Interim Results of the Phase II, Randomized, Controlled Dose- and Interval-ranging Study of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age-Related Macular Degeneration. Retina Society Conference, Boston, MA, October, 2007. 77. Are Recurrent Transient Rises in IOP a Concern for Patients Following Intravitreal Injections of Ranibizumab (Lucentis)? American Academy of Ophthalmology, New Orleans, LA, November 2007. 78. Continuous Intraocular Pressure Monitor, American Glaucoma Society, 79. The Effect of Prophylactic Glaucoma Medication on IOP Spikes after Intravitreal Injections, American Glaucoma Society, Washington D.C., March 2008. 80. Comparison of the Effect of Dose Titration on the Incidence of Hyperemia Associated with Initiation of Bimatoprost Therapy, American Glaucoma Society, Washington D.C., March 2008. 81. Complications of a Surgeon’s Initial Intravitreal Injections, ARVO, Fort 82. Does Central Corneal Thickness Change When IOP Significantly Increases? 83. What’s Really New in Ocular Pharmacotherapies? Treasure Coast Optometric 84. Optic Nerve Evaluation, The Clinician is Better Than the Machine, Challenges In Glaucoma, Update to Current Clinical Practice, Kresge Eye Institute, Wayne State University School of Medicine, September 20, 2008. 85. OCT and Fluorescein Angiographic Outcomes Through 1 Year for the Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular AMD, American Academy of Ophthalmology, Atlanta, GA, November 10, 2008. 86. Optical Coherence Tomography (Oct) Cross-Sectional Image of Live Tissue; A Virtual Biopsy, December 3, 2008, East Florida Eye Institute. 87. Amd Current Clinical Practice Patterns And Future Treatment Options A Retinal Investigators Insights, January 15, 2009, Treasure Coast Optometric Society. Superiority Of Vismed® (Sodium Hyaluronate Ophthalmic Solution 0.18%) Compared With Its Vehicle In The Treatment Of The Signs And Symptoms Of Dry Eye Disease, Association for Research and Vision in Ophthalmology, May 2009. The Effect of Prophylactic Use of IOP Lowering Medication on IOP Spikes After Intravitreal Injections, M.P. Frenkel, R.E.P. Frenkel, S. Haji, A Association for Research and Vision in Ophthalmology, May 2009. Continuous Monitoring of Intraocular Pressure with an Implantable Device, R.E. Frenkel, A, M. Jaeger, R. Kline-Schroeder, M.A. Latina, J.M. Parel, M.P.C. Frenkel, Association for Research and Vision in Ophthalmology, May 2009. Implantable Device for Continuous Monitoring of Intraocular Pressure, R.E. Frenkel, A, M. Jaeger, R. Kline-Schroeder, M.A. Latina, J.M. Parel, M.P.C. World Glaucoma Congress, July 2009. How Sensitive is Ophthalmoscopy in Detecting Optic Disc Hemorrhages in Clinical Practice? Haji, A., Frenkel, R.E.P., World Glaucoma Congress, July 2009. EFFECT OF DOSE TITRATION OF BIMATOPROST ON THE INCIDENCE OF HYPEREMIA, Haji, S., Frenkel, R., World Glaucoma Congress, July 2009. THE EFFECT OF PROPHYLACTIC USE OF ANTI-GLAUCOMA MEDICATIONS ON IOP SPIKES AFTER INTRAVITREAL INJECTIONS OF ANTI-VEGF FOR EXUDATIVE AMD, Frenkel, M., Frenkel, R.E.P., Frenkel, M. World Glaucoma Congress, July 2009. CLEAR-IT 2: Phase 2, Intravitreal VEGF Trap Eye in Patients With Neovascular Age-Related Macular Degeneration: Predictive Factors for Visual Acuity Outcome at One Year, J.S. Heier, CLEAR-IT 2 Investigators. Ophthalmic Consultants of Boston, Boston, MA, May 2009. VEGF Trap-Eye Vision-Specific Quality of Life Through 52 Weeks in Patients With Neovascular AMD in CLEAR-IT 2: A Phase 2 Clinical Trial, Johns Hopkins Wilmer Eye Inst, Baltimore, MD. May 2009 A Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap-Eye in Patients With Neovascular Age-Related Macular Degeneration: Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) Outcomes at 1 Year, Vitreous Retina Macula Consultants NY, New York, NY. May 2009. FEATURED IN PUBLICATIONS
1. Who’s Who in Medicine and Health Care, multiple editions, MARQUIS Who’s 2. Better by Half. Review of Ophthalmology, p. 82, January, 1998. 3. What’s Your UV Rating?, Stuart News, C1-2, June 30, 1998. 4. Antimetabolites are Used as Adjunctive Therapy. Ocular Surgery News, p. 30- 5. Glaucoma Drainage Implants are Equally Problematic. Ocular Surgery News, p. 6. Stuart Doctor: Glaucoma Drugs Fail at High Rate, A1-2, February 20, 1999. 7. A New Weapon in the War Against Glaucoma, Stuart News, E1-2, April 20, 8. Fewer Spots Needed with ALT Technique for IOP Control. Ophthalmology Times, Glaucoma Specialist Section p.48, March 15, 2000. 9. Arresting the Thief of Sight, Stuart News, D1-2, and January 16, 2001. 10. Update on Ocular Blood Flow in Glaucoma. Ophthalmology Management, p. 56- 11. New Approaches to Blood Flow Assessment, Review of Ophthalmology, Vol No 12. Beam Me Up, Doctor: New Laser May Help More Patients Avoid Surgery, Stuart 13. Macular Degeneration may go unnoticed for too long, 50 Plus, October 10, 2003. 14. Ocular Circulation and Oximetry society forms. Ophthalmology Times, 15. Soak Up Sun Safely, For Your Health, Summer, 2004, p. 8-10. 16. Stuart Ophthalmologist Makes Eye-Opening Find, Stuart News, October 26, 17. Back from Iraq, Soldier Makes Friendly Contacts, Stuart News, December 3, 18. Pegaptanib Sodium Leads to Significant Increase in Intraocular Pressure in Patients with Pre-Existing Glaucoma: Presented at ARVO, May 1, 2006, http://main.pslgroup.com/news. 19. Macugen May Present Risk of Increased IOP, May 2006, http://mdsupport.org/library/summary2006.html. 20. Developments in Vision Treatments, Hometown News, May 19, 2006. 21. East Florida Eye Institute, Helping Halt and Reverse a Devastating Eye Disease, 22. Study Raises Concerns Regarding IOP Spikes after Intravitreal Injections, EuroTimes, vol. 11, issue 7, special focus July 2006. 23. Keeping Glaucoma at Bay, Hometown News, April 13, 2007. 24. Pegaptanib Sodium Leads Increase in Intraocular Pressure in Patients With Glaucoma http://www.lens101.com/may-2006/1000-pegaptanib-sodium-leads-increase-intraocular-pressure-patients-glaucoma.html 25. Intravitreal injections of Lucentis and Avastin cause transient rises in intraocular pressure, Review of Optometry Online, Vol. No: 144:12 Issue: 12/14/2007 http://www.revoptom.com/index.asp?page=2_13650.htm. 26. MedPage November 15, 2007, Medical News from AAO: American Academy of Ophthalmology Meeting AAO: Intravitreal Injection of Angiogenesis Inhibitors Causes Pressure Spike http://www.medpagetoday.com/MeetingCoverage/AAO/tb/7375 27. Macugen causes worrying IOP spikes, Ophthalmology Times Europe, July 1, 2007, http://www.oteurope.com/ophthalmologytimeseurope/Ophthalmology+product+news/Implant-may-restore-sight-to-the-blind/ArticleStandard/Article/detail/449588 28. Anti-VEGF Therapies Show Low Incidence of Systemic Side Effects: Presented at AAO, Love Your Eyes.org.uk http://www.loveyoureyes.org.uk/content/view/94/33/. 29. Concern About Endophthalmitis Risk, IOP spikes following anti-vegf injections, EuroTimes, September 2007. http://www.escrs.org/PUBLICATIONS/EUROTIMES/07sept/Concernaboutendophthalmitis.pdf. 30. Clinical trial on age-related macular degeneration Venicegondelier.com http://www.venicegondolier.com/Newsstory.cfm?pubdate=012708&story=ff2.htm&folder=NewsArchive2. 31. DGDispatch Ranibizumab Injections Cause Spikes in Intraocular Pressure: Presented at AAO http://www.peerview-institute.org/news/content.nsf/MedicalNews/852571020057CCF6852573920058391D. 32. A Practice That Always Keeps an Eye On You, Hometown News, February 8, 33. Circadian Control of IOP Comparable with a Single Drop of Bimatoprost, Travoprost, Study Suggests http://www.osnsupersite.com/view.asp?rID=27802. 34. Ophthalmologist Gives Lecture at Kresge. Good For You, Scripps Treasure 35. The Need for Accurate, Continuous IP Measurements, Ophthalmology Times, October2008. http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma+Feature/Need-for-accurate-continuous-IOP-measurements-impe/ArticleStandard/Article/detail/556852?contextCategoryId=572 36. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain, Michael S. Korenfeld, MD, Steven M. Silverstein, MD, David L. Cooke, MD, Roger Vogel, MD, Robert S. Crockett, PhD,and the Difluprednate Ophthalmic Emulsion 0.05%, Ronald Frenkel, part of the (Durezol) Study Group, Journal of Cataract and Refractive Surgery, January, 2009, pps 27-34.

Source: http://www.efei.com/documents/RFCVUpdated5.8.09.pdf